3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00365950|
Recruitment Status : Completed
First Posted : August 18, 2006
Last Update Posted : August 18, 2006
|Condition or disease||Intervention/treatment||Phase|
|Deep Vein Thrombosis Pulmonary Embolism Deep Vein Thrombosis With Pulmonary Embolism||Drug: Duration of anticoagulation Drug: Warfarin duration||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism|
|Study Start Date :||September 1999|
|Estimated Study Completion Date :||December 2003|
- Death due to DVT/PE
- Failures of resolution, extension or recurrence of DVT and/or PE during and after treatment.
- Number of major haemorrhages.
- Comparison of length of Hospital stay between those given unfractionated heparin and those given low molecular weight heparin.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00365950
|Department of Chest Medicine, Llandough Hospital|
|Cardiff, Wales, United Kingdom, CF62 2XX|
|Department of Chest Medicine, Llandough Hospital,|
|Cardiff, Wales, United Kingdom, CF64 2XX|
|Study Chair:||Aziz Sheikh, MD,FRCGP||Research Committee of the British Thoracic Society|